02:05 AM EDT, 05/01/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to USD43 from USD40, implying 9.4x our 2025 EPADS estimate, at a slight discount to its three-year historical forward P/E average of 9.9x, justified in our view to reflect the concern on Vaccine segment. We keep our EPADS estimates of GBP3.40 for 2025 and GBP3.70 for 2026. We expect Specialty Medicines to continue being the key driver on the back of continued demand and growth opportunities from new launches (three out of five product approvals expected in 2025 are in Specialty Medicines), while the challenging environment for Vaccines is expected to persist in 2025. In Q1 2025, GSK posted 2% sales growth, slightly ahead consensus as Specialty Medicine segment (+16%) continued to compensate for another weak quarter of Vaccines sales (-8%, Arexvy was hit by the revised vaccination recommendation in the U.S. and Shingrix was impacted by lower demand). Core operating margin improved by 0.5%-pt Y/Y helped by favorable product mix, increased royalties, and a smaller increase in R&D costs.